TF1 : Comeback of a rising trend ?
Entry price | Target | Stop-loss | Potential |
---|
€7.58 |
€8.3 |
€7.3 |
+9.5% |
---|
TF1 reflects attractive technical aspects that could allow investors to expect a trend reversal over the medium term.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● In a short-term perspective, the company has interesting fundamentals.
Strengths● The company is in a robust financial situation considering its net cash and margin position.
● Historically, the company has been releasing figures that are above expectations.
● The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.65 for the 2019 fiscal year.
● The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
● The company is one of the best yield companies with high dividend expectations.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● For the last few months, analysts have been revising downwards their earnings forecast.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.